I have worked in biotech / biopharma for the last eight years as a founder / venture investor / operator coming from a non biology / chem background. It is an a

I have worked in biotech / biopharma for the last eight years as a founder / venture investor / operator coming from a non biology / chem background. It is an amazing space that needs more smart people from other domains Most engineers / tech VCs have been making initial forays into this world through bio-IT / software driven drug dev. This is potentially a really promising space, but I'd suggest starting with biopharma bc 1) it has been generating some of the best returns in venture the last few years and 2) being good at bio-IT requires a good understanding of biopharma and drug dev Biopharma / therapeutics has generated some of the best returns in venture the last few years but is still mostly dominated by specialist VCs and has almost no seed ecosystem (most startups that end up getting venture funding are seeded within the top funds), so there is huge opportunity for seed investors to find the good opportunities outside of the top 5-10 life sci funds. The number of funded biotech startups and seed investors has not increased in a decade despite a doubling in venture funding and the best m&a / IPO environment ever. It is possible for companies to go from seed to IPO in under five years and $5-10B+ m&a in ~5-7 year timeframes (some good timely examples here: https://lifescivc.com/2018/01/two-carts-two-charts-dissecting-returns-t-cell-therapy-ma/ https://lifescivc.com/2018/01/two-carts-two-charts-dissectin...) Finding the best opportunities in biopharma requires identifying the best science. This requires investors to be at least conversational in biology, chemistry and drug development and to utilize advisors / consultants / PhDs to dive deep into specific tech To orient yourself to the world of biopharma investing, id start by reading more of Bruce booths blogs (he is the author of the post I linked above). He is one of the few life sci VCs who blogs and is also a pioneer in seed-series A biotech investing Also I'd recommend following biopharma news and funding / m&a activity. If you see any investors / people you recognize in press releases call them up. If you see a deal that interests you, take a look at the scientific publications from the company and reach out to the authors and other scientists in the space to hear their thoughts